Skip to Content

Grisactin 500 (griseofulvin) Disease Interactions

There are 3 disease interactions with Grisactin 500 (griseofulvin):

Major

Griseofulvin (Includes Grisactin 500) ↔ hepatic dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of griseofulvin is contraindicated in patients with hepatocellular failure, as animal data has shown that this drug may cause hepatocellular necrosis. The use of griseofulvin has not been adequately studied in patients with liver disease, although it is known that griseofulvin is primarily metabolized by the liver. Therapy with griseofulvin should be administered very cautiously in patients with liver impairment, and the dosing adjusted or discontinued according to clinical response.

References

  1. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.
Major

Griseofulvin (Includes Grisactin 500) ↔ porphyria

Severe Potential Hazard, High plausibility. Applies to: Porphyria

The use of griseofulvin is contraindicated in patients with porphyria. Griseofulvin has been shown to cause disturbances in porphyrin metabolism in laboratory animals.

References

  1. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.
Moderate

Griseofulvin (Includes Grisactin 500) ↔ lupus erythematosus

Moderate Potential Hazard, Moderate plausibility. Applies to: Lupus Erythematosus

The use of griseofulvin has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease. Griseofulvin therapy should be withdrawn in patients experiencing worsening of preexisting lupus until another cause can be identified.

References

  1. Miyagawa S, Sakamoto K "Adverse reaction to griseofulvin in patients with circulating anti-ssa/ro and ssb/la autoantibodies." Am J Med 87 (1989): 99-102
  2. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K "Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin." J Am Acad Dermatol 21 (1989): 343-6
  3. Madhok R, Zoma A, Capell H "Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin." Br Med J (Clin Res Ed) 291 (1985): 249-50
  4. "Product Information. Fulvicin P/G (griseofulvin)." Schering Laboratories, Kenilworth, NJ.
View all 4 references

Grisactin 500 (griseofulvin) drug interactions

There are 357 drug interactions with Grisactin 500 (griseofulvin)

Grisactin 500 (griseofulvin) alcohol/food interactions

There is 1 alcohol/food interaction with Grisactin 500 (griseofulvin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide